The company is substantially advanced its development of the novel therapy for cardiac amyloidosis, employing Attruby. Initial clinical information indicates promising outcomes for those affected by a debilitating illness. This effort represents researchers’ focus to managing critical healthcare needs in this cardiology space. Attruby: BridgeBio